$BMRA News

Biomerica Reports First Quarter Fiscal 2027 Financial Results

Biomerica Q1 EPS $(0.37), Sales $1.265M Down From $1.380M YoY

Biomerica Files $250M Shelf Registration Statement For Mixed Securities Offering

Biomerica Files Prospectus Covering Resale Of Up To 1,403,705 Shares Of Common Stock By Selling Stockholders

Biomerica Reports Fiscal 2026 Year-End Financial Results

Biomerica Q4 EPS $(0.38) Up From $(0.69) YoY, Sales $875.000K Up From $749.000K YoY

Biomerica Announces $2.23 Million Financing

Biomerica Commences ~$2.23M Private Placement Of 1.394M Shares At $1.60 Per Share

Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development

Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026

Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway

Biomerica's Ethos Laboratories' Test Now Eligible For Medicare Coverage On Individual Basis Announced By Medicare Administrative Contractor

Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs

Biomerica Q3 EPS $(0.44) Up From $(0.48) YoY, Sales $987.000K Down From $1.119M YoY

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe

Biomerica Receives First Commercial Order For Hp Detect, Helicobacter Pylori Diagnostic Stool Antigen Test

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Biomerica Receives Registration From UK Medicines & Healthcare Products Regulatory Agency (MHRA) For hp+detect Diagnostic Tests For H. pylori bacteria

Biomerica Receives Registration From UK Medicines & Healthcare Products Regulatory Agency (MHRA) For hp+detect Diagnostic Tests For H. pylori bacteria